Alumis Inc. will discuss Phase 3 ONWARD trial data for envudeucitinib in psoriasis on January 6, 2026, at 8:00 a.m. ET.
Quiver AI Summary
Alumis Inc., a biopharma company focused on targeted therapies for immune-mediated diseases, announced that it will release topline data from its Phase 3 ONWARD clinical program evaluating envudeucitinib for moderate-to-severe plaque psoriasis on January 6, 2026. The company will hold a conference call and webcast at 8:00 a.m. ET the same day to discuss the results. Alumis specializes in developing next-generation therapies using data analytics and precision medicine approaches, with a pipeline that includes envudeucitinib and treatments for various immune-related conditions. The webcast will be available on their website, and a replay will be accessible afterward.
Potential Positives
- Alumis is set to report topline data from the Phase 3 ONWARD clinical program, which may signify important advancements in the treatment of moderate-to-severe plaque psoriasis.
- The upcoming conference call and webcast provide an opportunity for direct engagement with investors and stakeholders, enhancing transparency and communication regarding the company's progress.
- The development of envudeucitinib, alongside a robust pipeline of therapies for serious immune-mediated diseases, positions Alumis as a key player in the biopharmaceutical sector.
Potential Negatives
- Significant uncertainty surrounding the upcoming topline data report from the Phase 3 ONWARD clinical program, as the success of the product is crucial for the company's future prospects.
- Potential issues with investor confidence due to reliance on clinical trial results for the development of their therapies, which can be unpredictable.
- Company's status as a late-stage biopharma could indicate a higher risk, as they may face pressure to deliver successful outcomes in a competitive market.
FAQ
When will Alumis report the Phase 3 ONWARD clinical program results?
Alumis will report topline data from the Phase 3 ONWARD clinical program on Tuesday, January 6, 2026.
What time is the Alumis conference call and webcast?
The conference call and webcast will be held on January 6, 2026, at 8:00 a.m. ET.
How can I access the Alumis conference call and webcast?
You can access the live webcast at the provided link or through the "Events" page on Alumis' website.
Is there a replay available for the conference call?
Yes, a replay of the webcast will be available on the Company’s website following the call.
What therapies is Alumis developing for immune-mediated diseases?
Alumis is developing targeted therapies, including envudeucitinib and lonigutamab for various immune-mediated disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALMS Insider Trading Activity
$ALMS insiders have traded $ALMS stock on the open market 26 times in the past 6 months. Of those trades, 26 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALMS stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU has made 14 purchases buying 1,265,253 shares for an estimated $9,069,492 and 0 sales.
- JAMES B. TANANBAUM has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- CAPITAL MANAGEMENT VI LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- LABS, LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALMS Hedge Fund Activity
We have seen 65 institutional investors add shares of $ALMS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 1,558,660 shares (+809.7%) to their portfolio in Q3 2025, for an estimated $6,219,053
- MADISON AVENUE PARTNERS, LP removed 1,424,492 shares (-77.3%) from their portfolio in Q3 2025, for an estimated $5,683,723
- TANG CAPITAL MANAGEMENT LLC removed 829,788 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $3,310,854
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 674,163 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $2,689,910
- VANGUARD GROUP INC added 625,404 shares (+18.4%) to their portfolio in Q3 2025, for an estimated $2,495,361
- CANTOR FITZGERALD, L. P. removed 559,201 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,231,211
- UBS GROUP AG removed 444,880 shares (-36.8%) from their portfolio in Q3 2025, for an estimated $1,775,071
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALMS Analyst Ratings
Wall Street analysts have issued reports on $ALMS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/18/2025
- Morgan Stanley issued a "Overweight" rating on 08/15/2025
- Wells Fargo issued a "Overweight" rating on 07/25/2025
To track analyst ratings and price targets for $ALMS, check out Quiver Quantitative's $ALMS forecast page.
$ALMS Price Targets
Multiple analysts have issued price targets for $ALMS recently. We have seen 4 analysts offer price targets for $ALMS in the last 6 months, with a median target of $18.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $20.0 on 12/18/2025
- Terence Flynn from Morgan Stanley set a target price of $22.0 on 08/15/2025
- Derek Archila from Wells Fargo set a target price of $17.0 on 07/25/2025
Full Release
– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Conference Call and Webcast Details
Alumis’ conference call and webcast to discuss the topline data results from the Phase 3 ONWARD clinical program will begin Tuesday, January 6, 2026, at 8:00 a.m. ET. To access the live webcast please access this
link
or visit the “
Events
” page of the “Investors" section of the Alumis website at www.alumis.com. A replay of the webcast will be made available on the Company’s website following the call.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit
www.alumis.com
or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding the anticipated timing and availability of clinical data from the ONWARD Phase 3 clinical program. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
